By Colin Kellaher
Compass Therapeutics has hired Barry Shin as the clinical-stage biopharmaceutical company's new chief financial officer.
Compass on Tuesday said Shin most recently served as executive vice president and chief operating and financial officer at biopharmaceutical company Trevena.
Thomas Schuetz, Compass' chief executive, has been serving as the Boston company's principal financial officer.
Compass said Shin, 53 years old, will receive an annual base salary of $475,000, a $50,000 sign-on bonus and an annual bonus with a target of 45% of his base pay.
Write to Colin Kellaher at colin.kellaher@wsj.com
(END) Dow Jones Newswires
December 10, 2024 08:24 ET (13:24 GMT)
Copyright (c) 2024 Dow Jones & Company, Inc.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.